Glioblastoma in adults.
暂无分享,去创建一个
A. Brandes | M. Reni | G. Gatta | C. Vecht | E. Franceschi | A. Tosoni
[1] Robert G. Selker,et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma , 2009 .
[2] W. Curran,et al. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. , 2007, International journal of radiation oncology, biology, physics.
[3] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Brandes,et al. 2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034) , 2007 .
[5] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[6] A. Brandes,et al. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034 , 2007 .
[7] Luc Taillandier,et al. Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.
[8] Kjell Hansson Mild,et al. Long-term use of cellular phones and brain tumours: increased risk associated with use for ⩾10 years , 2007, Occupational and Environmental Medicine.
[9] A. Brandes,et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2007, British Journal of Cancer.
[10] A. Brandes,et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.
[11] E. Wong. Is protracted low-dose temozolomide feasible in glioma patients? , 2006, Neurology.
[12] R. Mirimanoff,et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Yue Cao,et al. Physiologic and metabolic magnetic resonance imaging in gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Omuro,et al. Salvage temozolomide for prior temozolomide responders , 2005, Cancer.
[15] B. Scheithauer,et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Susan M. Chang,et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.
[17] E. Rakovitch,et al. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. , 2005, Cancer treatment reviews.
[18] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[19] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[20] A. Brandes,et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Paola Pisani,et al. Genetic Pathways to Glioblastoma , 2004, Cancer Research.
[22] J. Dichgans,et al. One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma , 2004, Neurology.
[23] A. Brandes,et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] E. Bruera,et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Anssi Auvinen,et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries , 2004, International journal of cancer.
[26] E Carrani,et al. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] M. Weller,et al. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Grönberg,et al. Familial brain tumours—genetics or environment? A nationwide cohort study of cancer risk in spouses and first‐degree relatives of brain tumour patients , 2003, International journal of cancer.
[29] Susan M. Chang,et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] E. Shaw,et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Long,et al. Outcome and Cost of Craniotomy Performed to Treat Tumors in Regional Academic Referral Centers , 2003, Neurosurgery.
[32] R. Hellman,et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Jolles,et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study , 2002, The Lancet.
[34] M. Berger,et al. Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.
[35] A. Brandes,et al. Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study , 2002, Oncology.
[36] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[37] K. Hess,et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] M. J. van den Bent,et al. EORTC Brain Tumor Group: achievements and perspectives. , 2002, European journal of cancer.
[39] G. Reifenberger,et al. The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.
[40] M Brada,et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] H. Grönberg,et al. Genetic epidemiology of glioma , 2001, British Journal of Cancer.
[42] C. Amos,et al. Segregation analysis of cancer in families of glioma patients , 2001, Genetic epidemiology.
[43] M. member. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .
[44] M. J. van den Bent,et al. PCV chemotherapy for recurrent glioblastoma multiforme , 2001, Neurology.
[45] P Van Tassel,et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.
[46] G. Barger,et al. Discrepancies in diagnoses of neuroepithelial neoplasms , 2000, Cancer.
[47] P. L. Lee,et al. Magnetic resonance spectroscopy of brain tumors , 2000, Current opinion in oncology.
[48] A. Brandes,et al. Endocrine Dysfunctions in Patients Treated for Brain Tumors: Incidence and Guidelines for Management , 2000, Journal of Neuro-Oncology.
[49] J. Grau,et al. Radiotherapy of the brain in elderly patients , 2000 .
[50] M. Prados,et al. Response and progression in recurrent malignant glioma. , 1999, Neuro-oncology.
[51] Susan M. Chang,et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] S. Piantadosi,et al. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] D. Osoba,et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma , 1997, Journal of Neuro-Oncology.
[55] B. Scheithauer,et al. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma , 1997, Journal of Neuro-Oncology.
[56] R Miike,et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. , 1997, American journal of epidemiology.
[57] A. Gregor,et al. Radiotherapy for malignant glioma , 1996, BMJ.
[58] D. Nelson,et al. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose‐escalation trial for malignant glioma (radiation therapy oncology group 83‐02) , 1994, Cancer.
[59] D. Áfra,et al. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas , 1994, Neurology.
[60] E. Neuwelt,et al. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] B. Scheithauer,et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[63] H. Fine,et al. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[64] S. Green,et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. , 1992, Journal of neurosurgery.
[65] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] P. Gutin,et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.
[67] S B Green,et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. , 1989, Journal of neurosurgery.
[68] E. Alexander,et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. , 1989, International journal of radiation oncology, biology, physics.
[69] T. Trojanowski,et al. Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas , 1988, Journal of Neuro-Oncology.
[70] S B Green,et al. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] Jensen,et al. Combined modality treatment of operated astrocytomas grade 3–4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy , 1984 .
[72] D. Schoenfeld,et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.
[73] D. Nelson,et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. , 1983, International journal of radiation oncology, biology, physics.
[74] D. Áfra,et al. Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. , 1983, Journal of neurosurgery.
[75] D P Byar,et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.
[76] W. Simpson,et al. Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial , 1982, Cancer.
[77] R. Hatlevoll,et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.
[78] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[79] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[80] P. Band,et al. Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. , 1976, Journal of neurosurgery.
[81] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[82] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] H. Eyre,et al. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery , 2004, Journal of Neuro-Oncology.
[84] Susan M. Chang,et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.
[85] A. Friedman,et al. Chemotherapy for adults with malignant glioma. , 1999, Cancer investigation.
[86] M. Brada. Current approaches to radiation therapy for malignant gliomas. , 1999, Frontiers of radiation therapy and oncology.
[87] S. Piantadosi,et al. Central nervous system cancers in first-degree relatives and spouses. , 1999, Cancer investigation.
[88] M. Bernstein,et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. , 1998, International journal of radiation oncology, biology, physics.
[89] A. Brandes,et al. The role of chemotherapy in recurrent malignant gliomas: an overview. , 1996, Cancer investigation.
[90] D. Nelson,et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.
[91] K. Takakura,et al. Effects of ACNU and radiotherapy on malignant glioma. , 1986, Journal of neurosurgery.
[92] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[93] G. Bonadonna,et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. , 1979, Cancer clinical trials.
[94] M. Walker. The contemporary role of chemotherapy in the treatment of malignant brain tumor. , 1978, Clinical neurosurgery.
[95] Jacques Ferlay,et al. Cancer incidence in five continents. , 1976, IARC scientific publications.
[96] C. Sherman. [International Union Against Cancer]. , 1952, Jornal do medico.